Stock index futures were little changed on Tuesday as investors waited for the latest inflation data.
JPMorgan Chase (JPM) issued fresh guidance for 2026 on Tuesday, with its view for overall net interest income better than consensus and its expectation for expenses in line.
Here are some of Tuesday’s biggest stock movers:
Biggest stock gainers
- L3Harris Technologies (LHX) +14% Shares rose after the defense contractor announced a proposed $1B investment from the U.S. Department of Defense to significantly increase capacity to build solid rocket motors that power vital U.S. and allied missiles.
- Cardinal Health (CAH) +3.4% – The company increased its expectations for fiscal year 2026 non-GAAP diluted earnings per share to at least $10.00, from its prior guidance range of $9.65 to $9.85. It expects that its specialty revenues will surpass $50 billion in fiscal 2026, marking a 16% compounded annual growth rate (CAGR) over three years.
- Revvity (RVTY) +8.6% – Shares gained as the company now expects its full-year adjusted earnings per share to exceed the upper-end of the $4.90-$5.00 guidance provided on October 27, 2025. Reported and organic revenue growth for the fourth quarter is expected to be approximately 6% and 4%, respectively, as compared to the same period a year ago.
Biggest stock losers
- Concentrix (CNXC) 4.9% – Shares fell after the technology company forecast 2026 earnings per share that missed the average analyst estimate. First quarter reported revenue was projected at $2.475 billion to $2.500 billion vs $2.49B consensus.
- Delta Air Lines (DAL) 5.1% – Stock slipped in premarket trading after reporting Q4 results and setting profit guidance. The airline company reported operating revenue of $16.0B, operating income of $1.5B with an operating margin of 9.2%, pre-tax income of $1.5B with a pre-tax margin of 9.5%, and earnings per share of $1.55 for the quarter vs. $1.55 consensus and $1.55 a year ago.
- Travere Therapeutics (TVTX) 28.7% – Shares dropped after the company said it expects U.S. preliminary net product sales for Q4 2025 to be about $127M. The company expects FY25 U.S. net product sales of about $410M, and the year ended with roughly $323M in cash and marketable securities.